{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:45:10Z","timestamp":1787694310382,"version":"build-2784847793"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DIM Ile de France, DIM Th\u00e9rapie g\u00e9nique"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Maple syrup urine disease (MSUD) is a rare recessively inherited metabolic disorder causing accumulation of branched chain amino acids leading to neonatal death, if untreated. Treatment for MSUD represents an unmet need because the current treatment with life-long low-protein diet is challenging to maintain, and despite treatment the risk of acute decompensations and neuropsychiatric symptoms remains. Here, based on significant liver contribution to the catabolism of the branched chain amino acid leucine, we develop a liver-directed adeno-associated virus (AAV8) gene therapy for MSUD. We establish and characterize the <jats:italic>Bckdha<\/jats:italic> (<jats:italic>branched chain keto acid dehydrogenase a<\/jats:italic>)<jats:sup>\u2212\/\u2212<\/jats:sup> mouse that exhibits a lethal neonatal phenotype mimicking human MSUD. Animals were treated at P0 with intravenous human <jats:italic>BCKDHA<\/jats:italic> AAV8 vectors under the control of either a ubiquitous or a liver-specific promoter. <jats:italic>BCKDHA<\/jats:italic> gene transfer rescued the lethal phenotype. While the use of a ubiquitous promoter fully and sustainably rescued the disease (long-term survival, normal phenotype and correction of biochemical abnormalities), liver-specific expression of <jats:italic>BCKDHA<\/jats:italic> led to partial, though sustained rescue. Here we show efficacy of gene therapy for MSUD demonstrating its potential for clinical translation.<\/jats:p>","DOI":"10.1038\/s41467-022-30880-w","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T15:10:30Z","timestamp":1654614630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice"],"prefix":"10.1038","volume":"13","author":[{"given":"Cl\u00e9ment","family":"Pontoizeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Simon-Sola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clovis","family":"Gaborit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-5436","authenticated-orcid":false,"given":"Vincent","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Rotaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan","family":"Tual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-2391","authenticated-orcid":false,"given":"Pasqualina","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Grazia","family":"Biferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Arnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0589-0703","authenticated-orcid":false,"given":"Agn\u00e8s","family":"R\u00f6tig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Ottolenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"de Lonlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0264-0891","authenticated-orcid":false,"given":"Marina","family":"Cavazzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8272-232X","authenticated-orcid":false,"given":"Manuel","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"30880_CR1","unstructured":"Chuang, D. T. & Shih, V. E. In The Metabolic and Molecular Bases of Inherited Disease 1971\u20132006 (McGraw-Hill, 2001)."},{"key":"30880_CR2","unstructured":"Strauss, K. A. et al. In GeneReviews\u00ae [Internet]. (eds Adam, M. P. et al.) (University of Washington, Seattle, WA, 1993\u20132022)."},{"key":"30880_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1172\/JCI67217","volume":"123","author":"ER Muelly","year":"2013","unstructured":"Muelly, E. R. et al. Biochemical correlates of neuropsychiatric illness in maple syrup urine disease. J. Clin. Investig. 123, 1809\u20131820 (2013).","journal-title":"J. Clin. Investig."},{"key":"30880_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ymgme.2020.01.006","volume":"129","author":"KA Strauss","year":"2020","unstructured":"Strauss, K. A. et al. Branched-chain \u03b1-ketoacid dehydrogenase deficiency (maple syrup urine disease): treatment, biomarkers, and outcomes. Mol. Genet. Metab. 129, 193\u2013206 (2020).","journal-title":"Mol. Genet. Metab."},{"key":"30880_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10545-017-0033-7","volume":"40","author":"J Bouchereau","year":"2017","unstructured":"Bouchereau, J. et al. Neurocognitive profiles in MSUD school-age patients. J. Inherit. Metab. Dis. 40, 377\u2013383 (2017).","journal-title":"J. Inherit. Metab. Dis."},{"key":"30880_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10545-017-0083-x","volume":"40","author":"M-T Abi-Ward\u00e9","year":"2017","unstructured":"Abi-Ward\u00e9, M.-T. et al. Long-term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease. J. Inherit. Metab. Dis. 40, 783\u2013792 (2017).","journal-title":"J. Inherit. Metab. Dis."},{"key":"30880_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1023\/A:1026708618507","volume":"23","author":"A Bodner-Leidecker","year":"2000","unstructured":"Bodner-Leidecker, A., Wendel, U., Saudubray, J. M. & Schadewaldt, P. Branched-chain L-amino acid metabolism in classical maple syrup urine disease after orthotopic liver transplantation. J. Inherit. Metab. Dis. 23, 805\u2013818 (2000).","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 2","key":"30880_CR8","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1007\/PL00014324","volume":"158","author":"U Wendel","year":"1999","unstructured":"Wendel, U., Saudubray, J. M., Bodner, A. & Schadewaldt, P. Liver transplantation in maple syrup urine disease. Eur. J. Pediatr. 158(Suppl. 2), S60\u2013S64 (1999).","journal-title":"Eur. J. Pediatr."},{"key":"30880_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jpeds.2011.06.033","volume":"160","author":"GV Mazariegos","year":"2012","unstructured":"Mazariegos, G. V. et al. Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. J. Pediatr. 160, 116\u2013121.e1 (2012).","journal-title":"J. Pediatr."},{"key":"30880_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/ajcn\/68.1.72","volume":"68","author":"A Suryawan","year":"1998","unstructured":"Suryawan, A. et al. A molecular model of human branched-chain amino acid metabolism. Am. J. Clin. Nutr. 68, 72\u201381 (1998).","journal-title":"Am. J. Clin. Nutr."},{"key":"30880_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrg2988","volume":"12","author":"F Mingozzi","year":"2011","unstructured":"Mingozzi, F. & High, K. A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 12, 341\u2013355 (2011).","journal-title":"Nat. Rev. Genet."},{"key":"30880_CR12","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani, A. C. et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371, 1994\u20132004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"30880_CR13","doi-asserted-by":"publisher","unstructured":"Ginocchio, V. M., Ferla, R., Auricchio, A. & Brunetti-Pierri, N. Current status on clinical development of adeno-associated virus-mediated liver-directed gene therapy for inborn errors of metabolism. Hum. Gene Ther. https:\/\/doi.org\/10.1089\/hum.2019.151 (2019).","DOI":"10.1089\/hum.2019.151"},{"key":"30880_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05972-1","volume":"9","author":"J Baruteau","year":"2018","unstructured":"Baruteau, J. et al. Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by Asl gene transfer. Nat. Commun. 9, 3505 (2018).","journal-title":"Nat. Commun."},{"key":"30880_CR15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/gt.2013.53","volume":"20","author":"RJ Chandler","year":"2013","unstructured":"Chandler, R. J. et al. Liver-directed adeno-associated virus serotype 8 gene transfer rescues a lethal murine model of citrullinemia type 1. Gene Ther. 20, 1188\u20131191 (2013).","journal-title":"Gene Ther."},{"key":"30880_CR16","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/mt.2009.88","volume":"17","author":"SC Cunningham","year":"2009","unstructured":"Cunningham, S. C. et al. AAV2\/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice. Mol. Ther. 17, 1340\u20131346 (2009).","journal-title":"Mol. Ther."},{"key":"30880_CR17","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1038\/mt.2012.129","volume":"20","author":"EK Lee","year":"2012","unstructured":"Lee, E. K. et al. Long-term survival of the juvenile lethal arginase-deficient mouse with AAV gene therapy. Mol. Ther. 20, 1844\u20131851 (2012).","journal-title":"Mol. Ther."},{"key":"30880_CR18","doi-asserted-by":"publisher","unstructured":"Chandler, R. J. & Venditti, C. P. Gene therapy for methylmalonic acidemia: past, present, and future. Hum. Gene Ther. https:\/\/doi.org\/10.1089\/hum.2019.113 (2019).","DOI":"10.1089\/hum.2019.113"},{"key":"30880_CR19","doi-asserted-by":"publisher","unstructured":"Grisch-Chan, H. M., Schwank, G., Harding, C. O. & Th\u00f6ny, B. State-of-the-art 2019 on gene therapy for phenylketonuria. Hum. Gene Ther. https:\/\/doi.org\/10.1089\/hum.2019.111 (2019).","DOI":"10.1089\/hum.2019.111"},{"key":"30880_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-7-33","volume":"7","author":"GE Homanics","year":"2006","unstructured":"Homanics, G. E., Skvorak, K., Ferguson, C., Watkins, S. & Paul, H. S. Production and characterization of murine models of classic and intermediate maple syrup urine disease. BMC Med. Genet. 7, 33 (2006).","journal-title":"BMC Med. Genet."},{"key":"30880_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep28775","volume":"6","author":"D S Sonnet","year":"2016","unstructured":"S Sonnet, D. et al. Metformin inhibits branched chain amino acid (BCAA) derived ketoacidosis and promotes metabolic homeostasis in MSUD. Sci. Rep. 6, 28775 (2016).","journal-title":"Sci. Rep."},{"key":"30880_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/brain\/awp024","volume":"132","author":"WJ Zinnanti","year":"2009","unstructured":"Zinnanti, W. J. et al. Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease. Brain J. Neurol. 132, 903\u2013918 (2009).","journal-title":"Brain J. Neurol."},{"key":"30880_CR23","doi-asserted-by":"crossref","unstructured":"Taghavi, M. & Hutson, S. M. Generation of branched chain \u03b1-keto acid dehydrogenase enzyme complex E1\u03b1 knockout mouse models. FASEB J. 26, 1013.24 (abstr) (2012).","DOI":"10.1096\/fasebj.26.1_supplement.1013.24"},{"key":"30880_CR24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41586-019-1503-x","volume":"572","author":"T Yoneshiro","year":"2019","unstructured":"Yoneshiro, T. et al. BCAA catabolism in brown fat controls energy homeostasis through SLC25A44. Nature 572, 614\u2013619 (2019).","journal-title":"Nature"},{"key":"30880_CR25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s003350010149","volume":"11","author":"JA Rafael","year":"2000","unstructured":"Rafael, J. A., Nitta, Y., Peters, J. & Davies, K. E. Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmdmdxand Dmdmdx3cvdystrophin-deficient mice. Mamm. Genome 11, 725\u2013728 (2000).","journal-title":"Mamm. Genome"},{"key":"30880_CR26","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1042\/bj2950635","volume":"295","author":"H Koyata","year":"1993","unstructured":"Koyata, H., Cox, R. P. & Chuang, D. T. Stable correction of maple syrup urine disease in cells from a Mennonite patient by retroviral-mediated gene transfer. Biochem. J. 295, 635\u2013639 (1993). Pt 3.","journal-title":"Biochem. J."},{"key":"30880_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.omtm.2018.12.011","volume":"12","author":"F Collaud","year":"2019","unstructured":"Collaud, F. et al. Preclinical development of an AAV8-hUGT1A1 vector for the treatment of Crigler-Najjar syndrome. Mol. Ther. Methods Clin. Dev. 12, 157\u2013174 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"30880_CR28","doi-asserted-by":"publisher","first-page":"100763","DOI":"10.1016\/j.ymgmr.2021.100763","volume":"27","author":"L Guilder","year":"2021","unstructured":"Guilder, L. et al. Hyperleucinosis during infections in maple syrup urine disease post liver transplantation. Mol. Genet. Metab. Rep. 27, 100763 (2021).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"30880_CR29","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan, S. et al. AAV5\u2013factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519\u20132530 (2017).","journal-title":"N. Engl. J. Med."},{"key":"30880_CR30","doi-asserted-by":"crossref","unstructured":"Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713\u20131722 (2017).","DOI":"10.1056\/NEJMoa1706198"},{"key":"30880_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1484","author":"JR Mendell","year":"2020","unstructured":"Mendell, J. R. et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne Muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1484 (2020).","journal-title":"JAMA Neurol."},{"key":"30880_CR32","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1089\/hum.2013.233","volume":"25","author":"G Bortolussi","year":"2014","unstructured":"Bortolussi, G. et al. Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler\u2013Najjar syndrome. Hum. Gene Ther. 25, 844\u2013855 (2014).","journal-title":"Hum. Gene Ther."},{"key":"30880_CR33","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/mt.2011.151","volume":"19","author":"L Wang","year":"2011","unstructured":"Wang, L. et al. AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta). Mol. Ther. 19, 2012\u20132020 (2011).","journal-title":"Mol. Ther."},{"key":"30880_CR34","doi-asserted-by":"publisher","first-page":"16049","DOI":"10.1038\/mtm.2016.49","volume":"3","author":"G Ronzitti","year":"2016","unstructured":"Ronzitti, G. et al. A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome. Mol. Ther. Methods Clin. Dev. 3, 16049 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"30880_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.omtm.2018.11.002","volume":"12","author":"P Colella","year":"2019","unstructured":"Colella, P. et al. AAV gene transfer with tandem promoter design prevents anti-transgene immunity and provides persistent efficacy in neonate Pompe mice. Mol. Ther. Methods Clin. Dev. 12, 85\u2013101 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"30880_CR36","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1006\/mthe.2000.0075","volume":"1","author":"CH Miao","year":"2000","unstructured":"Miao, C. H. et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol. Ther. 1, 522\u2013532 (2000).","journal-title":"Mol. Ther."},{"key":"30880_CR37","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1172\/JCI200316887","volume":"111","author":"F Mingozzi","year":"2003","unstructured":"Mingozzi, F. et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Investig. 111, 1347\u20131356 (2003).","journal-title":"J. Clin. Investig."},{"key":"30880_CR38","doi-asserted-by":"publisher","first-page":"417.e4","DOI":"10.1016\/j.cmet.2018.10.013","volume":"29","author":"MD Neinast","year":"2019","unstructured":"Neinast, M. D. et al. Quantitative analysis of the whole-body metabolic fate of branched-chain amino acids. Cell Metab. 29, 417.e4\u2013429.e4 (2019).","journal-title":"Cell Metab."},{"key":"30880_CR39","doi-asserted-by":"publisher","unstructured":"Greig, J. A. et al. Muscle-directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model. Mol. Genet. Metab. https:\/\/doi.org\/10.1016\/j.ymgme.2021.08.003 (2021).","DOI":"10.1016\/j.ymgme.2021.08.003"},{"key":"30880_CR40","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/mt.2008.72","volume":"16","author":"SC Cunningham","year":"2008","unstructured":"Cunningham, S. C., Dane, A. P., Spinoulas, A., Logan, G. J. & Alexander, I. E. Gene delivery to the juvenile mouse liver using AAV2\/8 vectors. Mol. Ther. 16, 1081\u20131088 (2008).","journal-title":"Mol. Ther."},{"key":"30880_CR41","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature12875","volume":"506","author":"L Lisowski","year":"2014","unstructured":"Lisowski, L. et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506, 382\u2013386 (2014).","journal-title":"Nature"},{"key":"30880_CR42","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","volume":"107","author":"AC Nathwani","year":"2006","unstructured":"Nathwani, A. C. et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107, 2653\u20132661 (2006).","journal-title":"Blood"},{"key":"30880_CR43","doi-asserted-by":"publisher","first-page":"12400","DOI":"10.1016\/S0021-9258(18)42286-7","volume":"267","author":"RM Wynn","year":"1992","unstructured":"Wynn, R. M., Davie, J. R., Cox, R. P. & Chuang, D. T. Chaperonins groEL and groES promote assembly of heterotetramers (alpha 2 beta 2) of mammalian mitochondrial branched-chain alpha-keto acid decarboxylase in Escherichia coli. J. Biol. Chem. 267, 12400\u201312403 (1992).","journal-title":"J. Biol. Chem."},{"key":"30880_CR44","doi-asserted-by":"publisher","first-page":"13110","DOI":"10.1074\/jbc.273.21.13110","volume":"273","author":"RM Wynn","year":"1998","unstructured":"Wynn, R. M., Davie, J. R., Chuang, J. L., Cote, C. D. & Chuang, D. T. Impaired assembly of E1 decarboxylase of the branched-chain alpha-ketoacid dehydrogenase complex in type IA maple syrup urine disease. J. Biol. Chem. 273, 13110\u201313118 (1998).","journal-title":"J. Biol. Chem."},{"key":"30880_CR45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10545-017-0053-3","volume":"40","author":"J Baruteau","year":"2017","unstructured":"Baruteau, J., Waddington, S. N., Alexander, I. E. & Gissen, P. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. J. Inherit. Metab. Dis. 40, 497\u2013517 (2017).","journal-title":"J. Inherit. Metab. Dis."},{"key":"30880_CR46","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jhep.2013.04.004","volume":"59","author":"S Fagiuoli","year":"2013","unstructured":"Fagiuoli, S., Daina, E., D\u2019Antiga, L., Colledan, M. & Remuzzi, G. Monogenic diseases that can be cured by liver transplantation. J. Hepatol. 59, 595\u2013612 (2013).","journal-title":"J. Hepatol."},{"key":"30880_CR47","doi-asserted-by":"publisher","unstructured":"George, L. A. et al. Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol. Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.001 (2020).","DOI":"10.1016\/j.ymthe.2020.06.001"},{"key":"30880_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella, P., Ronzitti, G. & Mingozzi, F. Emerging issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 8, 87\u2013104 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"30880_CR49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"HC Verdera","year":"2020","unstructured":"Verdera, H. C., Kuranda, K. & Mingozzi, F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol. Ther. 28, 723\u2013746 (2020).","journal-title":"Mol. Ther."},{"key":"30880_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-06621-3","volume":"9","author":"A Meliani","year":"2018","unstructured":"Meliani, A. et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 1\u201313 (2018).","journal-title":"Nat. Commun."},{"key":"30880_CR51","doi-asserted-by":"publisher","first-page":"14033","DOI":"10.1038\/mtm.2014.33","volume":"1","author":"M Corti","year":"2014","unstructured":"Corti, M. et al. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol. Ther. Methods Clin. Dev. 1, 14033 (2014).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"30880_CR52","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","volume":"26","author":"C Leborgne","year":"2020","unstructured":"Leborgne, C. et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat. Med. 26, 1096\u20131101 (2020).","journal-title":"Nat. Med."},{"key":"30880_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-57893-z","volume":"10","author":"B Bertin","year":"2020","unstructured":"Bertin, B. et al. Capsid-specific removal of circulating antibodies to adeno-associated virus vectors. Sci. Rep. 10, 1\u201311 (2020).","journal-title":"Sci. Rep."},{"key":"30880_CR54","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.omtm.2020.01.004","volume":"16","author":"A Orlowski","year":"2020","unstructured":"Orlowski, A. et al. Successful transduction with AAV vectors after selective depletion of anti-AAV antibodies by immunoadsorption. Mol. Ther. Methods Clin. Dev. 16, 192\u2013203 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"30880_CR55","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/mt.2013.244","volume":"22","author":"L Chicoine","year":"2014","unstructured":"Chicoine, L. et al. Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol. Ther. 22, 338\u2013347 (2014).","journal-title":"Mol. Ther."},{"key":"30880_CR56","doi-asserted-by":"publisher","first-page":"21150","DOI":"10.1073\/pnas.1906182116","volume":"116","author":"B Truong","year":"2019","unstructured":"Truong, B. et al. Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency. Proc. Natl Acad. Sci. USA 116, 21150\u201321159 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30880_CR57","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342\u2013347 (2006).","journal-title":"Nat. Med."},{"key":"30880_CR58","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0076-6879(00)24218-3","volume":"324","author":"N Nakai","year":"2000","unstructured":"Nakai, N., Kobayashi, R., Popov, K. M., Harris, R. A. & Shimomura, Y. Determination of branched-chain alpha-keto acid dehydrogenase activity state and branched-chain alpha-keto acid dehydrogenase kinase activity and protein in mammalian tissues. Methods Enzymol. 324, 48\u201362 (2000).","journal-title":"Methods Enzymol."},{"key":"30880_CR59","doi-asserted-by":"publisher","first-page":"e0150376","DOI":"10.1371\/journal.pone.0150376","volume":"11","author":"AG Wessels","year":"2016","unstructured":"Wessels, A. G. et al. High leucine diets stimulate cerebral branched-chain amino acid degradation and modify serotonin and ketone body concentrations in a pig model. PLoS ONE 11, e0150376 (2016).","journal-title":"PLoS ONE"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30880-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30880-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30880-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:41:23Z","timestamp":1669311683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30880-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["30880"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-30880-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"25 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.M. and M.-G.B. are employees and equity holders of Spark Therapeutics, a Roche company. We declare that C.P., M.S.-S., P.d.L., C.O., M.C., and M.S. are designated as inventors of the European Patent Application EP20305079.4 filed on Jan. 29, 2020 in the names of Inserm, Fondation Imagine, Universit\u00e9 de Paris, and APHP for \u201cGene therapy for MSUD.\u201d The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3278"}}